<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478556</url>
  </required_header>
  <id_info>
    <org_study_id>F070208011</org_study_id>
    <secondary_id>Omnipaque vs Gastroview Oral</secondary_id>
    <nct_id>NCT00478556</nct_id>
  </id_info>
  <brief_title>Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT</brief_title>
  <official_title>Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are scheduled by their health care provider for routine computed tomography (CT)
      scan will be asked to participate in this study. The primary purpose is to determine if there
      is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for
      abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference
      in bowel opacification for the two agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants must be scheduled for a CT scan prior to enrollment in this study. Informed
      consent will be obtained from patients acceptable to be included in the study. It will be
      noted if there is a history of gastrointestinal surgery and if the patient is nauseated
      before the contrast is administered.

      Patients will be randomized to receive either a standardized dilution of Gastroview or
      Omnipaque orally. The two agents will be prepared to have nearly equivalent iodine
      concentration. No flavoring agent (ie Crystal Light) will be added. The plan is to mix the
      agents per manufacturer recommendation as follows:

      Omnipaque 350 26cc in 974 cc of water (9.0g iodine) Gastroview 25cc in 1000cc of water (9.17g
      iodine)

      The time the patients start and stop consuming the contrast as well as the volume taken and
      time from first drink to start of the scan will be recorded by a blinded investigator.
      Patients will be asked to drink 900cc. Technical staff will report any side effects or
      complications observed.

      After completion of the CT scan, patients will fill in a survey rating the taste of the agent
      on a 5 point scale, and will be asked to report any side effects. Planned rating scale is as
      follows:

        -  2=Dislike very much

        -  1=Dislike moderately 0=Neither like nor dislike

             -  1=Like moderately

             -  2=Like very much

      A taste test between the two agents will then be administered by a blinded investigator.
      Patients will be given 30 cc of each agent. The order in which the agents are administered
      will be randomized. Patients will be asked to rate preference, if any, for either agent on a
      3 point scale. Potential bias related to which agent was administered for the CT will
      analyzed from the data.

      Planned rating scale is as follows:

        -  1- A is better 0 -no difference

             -  1- B is better

      Patients will be contacted by telephone the day after the CT to assess for any delayed side
      effects such as diarrhea, constipation, and abdominal cramping experienced in the 24 hours
      following.

      Bowel opacification will be rated by 2 body imagers blinded to the agent the patient
      received. Degree of opacification of the stomach, duodenum, jejunum, and ileum will be rated
      on a 4 point scale. If contrast has reached the colon, ascending, transverse, descending and
      sigmoid will be similarly evaluated. Four point rating scale is as follows:

      0= absent opacification

        1. minimal (&lt;25% of analyzed segments opacified)

        2. good (&gt;25 % and &lt; 75% of analyzed segments opacified)

        3. excellent (&gt; 75% of analyzed segments opacified)

      Description of tests/procedures to be performed. Patients will undergo contrast enhanced
      abdominal pelvis CT as ordered by the referring clinician. Patients will be randomized to
      either dilute Omnipaque or dilute Gastroview for oral contrast. Both agents will be in a
      concentration of 9 mg of iodine/ml, and a volume of 900 cc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preferred Contrast Agent</measure>
    <time_frame>1 Day</time_frame>
    <description>The primary outcome variable is the taste test when subjects will be asked which preparation they prefer. Possible answers include Onmipaque, Gastroview or neither.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel Opacification Score</measure>
    <time_frame>Collected day of study</time_frame>
    <description>The bowel opacification score was calculated by adding values for stomach, duodenum, jejunum and ileum for each patient. They were averaged across two doctors who read the studies. Scores can range from 0 (no opacification) to 3 (excellent) for each segment and from 0 to 12 for bowel opacification score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gastroview</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omnipaque</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omnipaque</intervention_name>
    <description>Oral CT contrast</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Iohexol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastroview</intervention_name>
    <description>Oral CT contrast</description>
    <arm_group_label>1</arm_group_label>
    <other_name>diatrizoate meglumine and diatrizoate sodium solution USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 19 years of age scheduled for outpatient contrast enhanced abdominal
             pelvic CT at The Kirklin Clinic in Birmingham Alabama as part of clinical care with
             the patient's provider will be screened for eligibility.

        Exclusion Criteria:

          -  Not competent to give consent.

          -  Pregnant.

          -  Known allergy to either of the contrast agents.

          -  Loss of sense of taste or smell.

          -  Contraindication to oral administration such as aspiration risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle McNamara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2007</study_first_posted>
  <results_first_submitted>February 9, 2010</results_first_submitted>
  <results_first_submitted_qc>May 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2010</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michelle McNamara, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CT scan</keyword>
  <keyword>oral contrast</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be randomized to receive either a standardized dilution of Gastroview or Omnipaque orally. The two agents will be prepared to have nearly equivalent iodine concentration.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gastroview Group</title>
          <description>Patients will be given oral Gastroview (contrast) prior to Computerized Tomography (CT).</description>
        </group>
        <group group_id="P2">
          <title>Omnipaque Group</title>
          <description>Patients ill be given oral Omnipaque (contrast) prior to Computerized Tomography (CT).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gastroview</title>
          <description>Oral Gastroview prior to CT</description>
        </group>
        <group group_id="B2">
          <title>Omnipaque</title>
          <description>Oral Omnipaque prior to CT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="15"/>
                    <measurement group_id="B2" value="57" spread="15"/>
                    <measurement group_id="B3" value="57" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preferred Contrast Agent</title>
        <description>The primary outcome variable is the taste test when subjects will be asked which preparation they prefer. Possible answers include Onmipaque, Gastroview or neither.</description>
        <time_frame>1 Day</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Gastroview</title>
            <description>Oral Gastroview prior to CT</description>
          </group>
          <group group_id="O2">
            <title>Omnipaque</title>
            <description>Oral Omnipaque prior to CT</description>
          </group>
        </group_list>
        <measure>
          <title>Preferred Contrast Agent</title>
          <description>The primary outcome variable is the taste test when subjects will be asked which preparation they prefer. Possible answers include Onmipaque, Gastroview or neither.</description>
          <population>Analysis was per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prefer Gastroview</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer Omnipaque</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All individuals tasted both preparations and indicated preference. A binomial test of proportion was done to see if these values differed from 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Binomial test of proportion</method>
            <method_desc>tested if values were different from 50%</method_desc>
            <param_type>difference in proportions</param_type>
            <param_value>62</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Opacification Score</title>
        <description>The bowel opacification score was calculated by adding values for stomach, duodenum, jejunum and ileum for each patient. They were averaged across two doctors who read the studies. Scores can range from 0 (no opacification) to 3 (excellent) for each segment and from 0 to 12 for bowel opacification score.</description>
        <time_frame>Collected day of study</time_frame>
        <population>per protocol - all patients had usable data</population>
        <group_list>
          <group group_id="O1">
            <title>Gastroview</title>
            <description>Oral Gastroview prior to CT</description>
          </group>
          <group group_id="O2">
            <title>Omnipaque</title>
            <description>Oral Omnipaque prior to CT</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Opacification Score</title>
          <description>The bowel opacification score was calculated by adding values for stomach, duodenum, jejunum and ileum for each patient. They were averaged across two doctors who read the studies. Scores can range from 0 (no opacification) to 3 (excellent) for each segment and from 0 to 12 for bowel opacification score.</description>
          <population>per protocol - all patients had usable data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="1.96"/>
                    <measurement group_id="O2" value="8.85" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum test was used to assess differences in bowel opacification score between the two groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gastroview</title>
          <description>Oral Gastroview prior to CT</description>
        </group>
        <group group_id="E2">
          <title>Omnipaque</title>
          <description>Oral Omnipaque prior to CT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Nelson</name_or_title>
      <organization>UAB Hospital Radiology</organization>
      <phone>205-934-4015</phone>
      <email>lnelson@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

